222 related articles for article (PubMed ID: 16796815)
1. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors.
Jinga DC; Blidaru A; Condrea I; Ardeleanu C; Dragomir C; Szegli G; Stefanescu M; Matache C
J Cell Mol Med; 2006; 10(2):499-510. PubMed ID: 16796815
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
3. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
4. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].
Zhang B; Liu YX; Cao WF; Cao XC; Ning LS; Hao XS
Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):471-6. PubMed ID: 19035119
[TBL] [Abstract][Full Text] [Related]
7. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.
Figueira RC; Gomes LR; Neto JS; Silva FC; Silva ID; Sogayar MC
BMC Cancer; 2009 Jan; 9():20. PubMed ID: 19144199
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
[TBL] [Abstract][Full Text] [Related]
10. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases.
Ree AH; Florenes VA; Berg JP; Maelandsmo GM; Nesland JM; Fodstad O
Clin Cancer Res; 1997 Sep; 3(9):1623-8. PubMed ID: 9815852
[TBL] [Abstract][Full Text] [Related]
11. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
Maeta H; Ohgi S; Terada T
Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
[TBL] [Abstract][Full Text] [Related]
12. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
[TBL] [Abstract][Full Text] [Related]
13. Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.
Brun JL; Cortez A; Lesieur B; Uzan S; Rouzier R; Daraï E
Oncol Rep; 2012 Apr; 27(4):1049-57. PubMed ID: 22200690
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.
Jobim FC; Xavier NL; Uchoa DM; Cruz DB; Saciloto M; Chemello N; Schwartsmann G
Braz J Med Biol Res; 2009 Oct; 42(10):979-87. PubMed ID: 19787153
[TBL] [Abstract][Full Text] [Related]
15. Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.
Zhang B; Cao X; Liu Y; Cao W; Zhang F; Zhang S; Li H; Ning L; Fu L; Niu Y; Niu R; Sun B; Hao X
BMC Cancer; 2008 Mar; 8():83. PubMed ID: 18373849
[TBL] [Abstract][Full Text] [Related]
16. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland.
Nagel H; Laskawi R; Wahlers A; Hemmerlein B
Histopathology; 2004 Mar; 44(3):222-31. PubMed ID: 14987225
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
20. Role of matrix metalloproteinase (MMP) 2 and MMP-9 in soft tissue sarcoma.
Yang HK; Jeong KC; Kim YK; Jung ST
Clin Orthop Surg; 2014 Dec; 6(4):443-54. PubMed ID: 25436070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
